BOSTON--(BUSINESS WIRE)--Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a target ...
Arnatar Therapeutics has unveiled with $52 million in series A financing to bankroll new RNA-based therapies, including a candidate that takes aim at a rare genetic disease called Alagille syndrome ...
Patients receiving a kidney transplant and who are positive for BK virus (BKV) are at risk of losing their transplant due to BKV reactivation. At this time, there are no antiviral options available ...
CD Bioparticles launches specialized RNA Synthesis services for researchers to develop next-generation mRNA vaccines, gene therapies, and RNA-based therapeutics.
Researchers from Osaka University have developed a novel approach to target nicotinamide N-methyltransferase (NNMT), an enzyme implicated in cancer progression, using antisense oligonucleotides (ASOs) ...
Assessing the distribution of a medication in the brain is critical for the treatment of a vast range of neurological disorders, especially conditions such as Parkinson's and Alzheimer's diseases. To ...
Patients treated with high-dose BIIB080 saw positive trends on the global Clinical Dementia Rating Sum of Boxes, Mini-Mental State Exam cognitive scales and Functional Activities Questionnaire at week ...
Discover how a newly developed platform technology from The University of North Carolina at Chapel Hill can enhance RNAi ...
A drug that halts an AIDS-related eye infection could be the first antisense therapy to reach the market. However, whether the drug can truly be called "antisense" depends on some specifics--such as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results